GSK licenses BioWa antibody potency technology
This article was originally published in Scrip
Executive Summary
BioWa has non-exclusively licensed rights to its Potelligent antibody potency-enhancing technology toGlaxoSmithKline, which will apply it to multiple, selected development-stage antibodies. The technology enhances antibody-dependent cellular cytotoxicity by reducing the amount of antibody fucose, using a fucosyl transferase gene knockout cell production system. BioWa, a wholly owned US subsidiary of Japan's Kyowa Hakko Kirin, will receive undisclosed up front, milestone and sales royalty payments as part of the agreement.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.